Abstract:<p>These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice review the diagnosis, management and prevention of post‐transplant lymphoproliferative disorders (PTLD) and other Epstein‐Barr virus (EBV) syndromes after solid organ transplantation. PTLD are a heterogeneous spectrum of predominantly B cell disorders, often extra‐nodal, with complex distinct pathogeneses and variable clinical presentations determined by pathologic subtype. Recent epidemiologic studies report a decrease in early EBV positive (+) PTLD and an increase in late EBV negative (‐) PTLD. Pre‐transplant EBV seronegativity and primary EBV infection, often from donor‐transmitted infection, is an important risk factor for EBV syndromes and early EBV+ PTLD. Low quality evidence supports pre‐emptive prevention strategies for early EBV+ PTLD in EBV seronegative recipients that involve EBV DNA measurement in peripheral blood using assays requiring further result harmonization, combined with interventions to lower viral load. Reduction in immunosuppression [RIS] is the best validated intervention. WHO pathology classification of a tissue biopsy remains the gold standard for PTLD diagnosis; optimal staging procedures are uncertain. Treatment of CD20+ PTLD with the response‐dependent sequential use of RIS, rituximab and cytotoxic chemotherapy is recommended. Evidence gaps requiring future research and alternate treatment strategies including immunotherapy are highlighted.</p><p>This article is protected by copyright. All rights reserved.</p>

Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice